Fig. 7
- ID
- ZDB-FIG-230614-7
- Publication
- Grissenberger et al., 2022 - High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-XL inhibition against Ewing sarcoma
- Other Figures
- All Figure Page
- Back to All Figure Page
Fig. 7. Mouse PDX experiments A) Female Swiss nude mice were transplanted with IC-pPDX-87 tumor fragments and treated with either A-1331852 (10 mg/kg twice per week), or S64315 (20 mg/kg once a week) or the respective combination for 14 days. B) Tumor sizes were measured twice a week and relative tumor volumes were calculated. C) Mice were weighed twice per week and relative weight was calculated. D) x-fold tumor size change compared to control group 14 days after the initiation of treatment was calculated. A tumor was considered to be responsive to therapy, when the x-fold change of tumor size was below 0.5. This was the case for 17% (1/6 mice) treated with S64315, 0% (0/6 mice) treated with A-1331852 and 50% (4/8 mice) treated with the combination. Statistical analyses were performed with a Kruskal-Wallis test, *: p ≤ 0.05. Error bars represent SEM of combined mice (6–8 per group). |